Autoimmune & Rheumatology Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol

This Phase 3 study is exploring a new way to predict flare-ups in people with systemic lupus erythematosus (SLE) by using molecular profiling. By identifying which patients are more likely to experience flares, doctors may be able to personalize treatments and monitoring plans better. The study is ongoing in France and collects various biological samples over two years to improve understanding of this unpredictable disease.

Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)

This Phase 4 trial is testing whether monitoring the levels of the rheumatoid arthritis drug adalimumab can help maintain disease control. The goal is to find the right medication dose for each patient to prevent flare-ups and improve long-term management. Conducted across several countries, this study follows participants for 18 months and could lead to more tailored treatment plans for adults with rheumatoid arthritis.

Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering

In this Phase 3 study, researchers are comparing two ways to reduce corticosteroid doses in patients with giant cell arteritis. The aim is to find a shorter or less intense treatment that still controls the disease but with fewer side effects. Recruiting patients in France, this trial hopes to improve quality of life by minimizing the risks linked to long-term steroid use.

Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)

This Phase 3 trial is evaluating olokizumab, an injectable medicine, for adults with polymyalgia rheumatica, a condition causing muscle pain and stiffness. If effective, olokizumab could offer an alternative to steroids, which are commonly used but can have significant side effects. The study is mainly conducted in Russia and is currently active but not recruiting, with results expected after the trial’s completion.

Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

This Phase 2 study tested a non-invasive ultrasound treatment combined with topical patches for knee osteoarthritis pain. This approach aims to reduce pain and improve joint function without surgery or systemic medications. The trial completed with over 300 participants in the United States, and while results are not yet available, this treatment could become a new option for managing osteoarthritis symptoms.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.